Japan Cancer Biomarkers Market Expected to Reach USD 3,621.3 Million by 2033 - IMARC Group

February 12, 2025 | Healthcare

VIEW FULL TABLE OF CONTENTS

Japan Cancer Biomarkers Market Statistics, Outlook and Regional Analysis 2025-2033

The Japan cancer biomarkers market size was valued at USD 1,252.6 Million in 2024, and it is expected to reach USD 3,621.3 Million by 2033, exhibiting a growth rate (CAGR) of 11.2% from 2025 to 2033.

Japan Cancer Biomarkers Market

To get more information on this market, Request Sample

Collaborative international initiatives are fostering cancer treatment innovation by connecting healthcare ecosystems, allowing for advanced therapeutic development, and expanding opportunities for researchers and medical innovators to address healthcare challenges with local expertise. For example, in December 2024, the Texas Medical Center (TMC) partnered with Japan's Mitsui Fudosan Co., Ltd., along with the National Cancer Center for launching the TMC Japan BioBridge and Japan-Accelerator Cancer Therapeutics and Medical Devices (JACT). This strategic alliance aims to advance cancer treatments and provide Japanese innovators with pathways to expand into the U.S. market.

Moreover, the use of artificial intelligence and genetic testing is promoting customized cancer therapy, with an emphasis on using data-driven insights to improve diagnostic precision and therapeutic results, reflecting the growing integration of technology in healthcare systems. For instance, in June 2024, SoftBank Group and Tempus AI established a joint venture to utilize artificial intelligence for analyzing personal medical data and providing treatment recommendations in Japan. This collaboration marks Tempus's first expansion of its genomic testing and AI-informed clinical recommendations services outside the U.S., aiming to enhance personalized cancer treatment in Japan. Furthermore, companies in the Japan cancer biomarkers market are using advances in precision medicine to improve diagnosis accuracy and treatment results. Besides this, they are working to address the inflating requirement for personalized healthcare solutions. Additionally, the market provides a considerable opportunity for companies to capitalize on expanding healthcare investments. Also, biomarker-based diagnostics are increasingly preferred by healthcare practitioners and patients over traditional approaches due to their capacity to give tailored and efficient findings. For example, biomarker-based oncology tests are becoming more popular in Japan, owing to programs such as the National Cancer Center's precision medicine program. This initiative works with pharmaceutical firms and research institutes to provide breakthrough biomarker solutions appropriate for Japanese populations, allowing for earlier identification, enhanced treatment planning, and better patient outcomes throughout the country.

Japan Cancer Biomarkers Market Statistics, By Region

The market research report has also provided a comprehensive analysis of all the major regional markets, which include the Kanto region, Kansai/Kinki region, Central/ Chubu region, Kyushu-Okinawa region, Tohoku region, Chugoku region, Hokkaido region, and Shikoku region. Advancements in molecular biology and genomics in various regions of Japan are inflating the overall market.

Kanto Region Cancer Biomarkers Market Trends:

Comprehensive cancer genome screening is gaining popularity in the Kanto region. The National Cancer Center Japan's SCRUM-Japan initiative focuses on genomic analysis for personalized oncology. The initiative collaborates with pharmaceutical firms to identify biomarkers for targeted medicines, notably for lung and gastrointestinal malignancies. This effort incorporates cutting-edge genetic profiling into clinical practice, allowing patients to get individualized therapies while also meeting the region's demand for precision medicine solutions.

Kansai/Kinki Region Cancer Biomarkers Market Trends:

The Kansai/Kinki region focuses on biomarkers for immunotherapy breakthroughs. Kyoto University and Takeda Pharmaceutical are working together to create immune checkpoint inhibitor indicators like PD-L1, which will help patients with lung cancer and melanoma choose the best treatment. This alliance brings together academic research and pharmaceutical expertise to advance clinical applications. With Kansai/Kinki's strong healthcare infrastructure, biomarker advancements are quickly converted into effective treatment alternatives, making immunotherapy more accessible and impactful in cancer care.

Central/Chubu Region Cancer Biomarkers Market Trends:

Early diagnosis of liver and prostate cancer with advanced diagnostics is a major trend in the Central/Chubu region. Fujirebio, located in Nagoya, has developed Lumipulse assays that use automation to detect cancer biomarkers with high accuracy. Its technologies are commonly employed in local hospitals and laboratories. By incorporating biomarker-based diagnostics into routine healthcare, Fujirebio promotes early cancer diagnosis, addresses regional healthcare concerns with dependable and precise solutions, strengthens Central/Chubu's medical expertise, etc.

Kyushu-Okinawa Region Cancer Biomarkers Market Trends:

Biomarker discovery for stomach cancer is a growing trend in Kyushu-Okinawa. Mirai Genomics in Fukuoka uses AI-powered systems to find actionable genetic alterations in stomach cancer, which is widespread in the region. By collaborating with local healthcare experts, they guarantee that biomarkers are clinically applicable, allowing for precision oncology. This invention tackles the high gastric cancer burden in Kyushu-Okinawa by improving diagnosis accuracy and personalizing treatment techniques based on regional patient requirements.

Tohoku Region Cancer Biomarkers Market Trends:

There is an emphasis on radiation-induced cancer biomarker research in the Tohoku region. Tohoku University has partnered with Hitachi to find biomarkers for thyroid cancer, addressing post-Fukushima healthcare concerns. These biomarkers enhance diagnoses and monitoring for radiation-exposed people. Tohoku's activities contribute to national cancer databases while also providing specific remedies for populations affected by radiation-related cancer risks.

Chugoku Region Cancer Biomarkers Market Trends:

Colorectal cancer biomarker research is a major trend in the Chugoku region. Okayama University works with Hiroshima-based biotech companies to create early-stage biomarkers using transcriptomics and metabolomics. These activities are intended to increase colorectal cancer screening accuracy. By concentrating on non-invasive diagnostics, this study meets regional healthcare requirements by improving early diagnosis and lowering mortality rates for one of the region's prevalent tumors.

Hokkaido Region Cancer Biomarkers Market Trends:

Esophageal cancer biomarker development tailored to lifestyle and dietary factors is a notable trend in Hokkaido. Hokkaido University identifies genetic and environmental biomarkers unique to the region. Collaborating with biotech companies, they focus on creating diagnostic tools for early detection. These advancements align with regional healthcare priorities, addressing the high incidence of esophageal cancer and improving outcomes through targeted diagnostics and personalized treatments.

Shikoku Region Cancer Biomarkers Market Trends:

Shikoku prioritizes liver cancer biomarker innovation to combat hepatitis-related cancer. Tokushima University combines proteomics and glycomics to create non-invasive indicators for early detection. These initiatives, which involve collaboration with pharmaceutical companies and local hospitals, improve the diagnosis accuracy of liver cancer. This strategy tackles Shikoku's high hepatitis prevalence by enhancing healthcare delivery and allowing for more effective therapies for liver-related cancers in the region.

Top Companies Leading in the Japan Cancer Biomarkers Industry

Some of the leading Japan cancer biomarkers market enterprises have been encompassed in the report. In June 2024, SoftBank Group and Tempus AI established a joint venture to utilize artificial intelligence for analyzing personal medical data and providing treatment recommendations in Japan. This collaboration marks Tempus's first expansion of its genomic testing and AI-informed clinical recommendations services outside the U.S., aiming to enhance personalized cancer treatment in Japan.

Japan Cancer Biomarkers Market Segmentation Coverage

Based on the profiling technology, the market has been classified into omic technologies, imaging technologies, immunoassays, and cytogenetics. Omic technologies such as metabolomics enable cancer analysis at the molecular level. Imaging technologies, including PET and MRI, provide accurate tumor imaging. Immunoassays identify biomarkers with high specificity, facilitating diagnosis. Cytogenetics analyzes chromosomal abnormalities to provide personalized therapy solutions that improve patient outcomes.
Based on the biomolecule, the market has been categorized into genetic biomarkers, protein biomarkers, and glyco-biomarkers. Genetic biomarkers identify particular gene mutations or changes associated with cancer, allowing for early identification, risk assessment, and individualized treatment regimens. Protein biomarkers are used to analyze tumor-associated proteins, aid in cancer diagnosis and prognosis, and monitor therapy efficacy. Glyco-biomarkers identify changes in glycosylation patterns, allowing researchers to understand cancer better and develop targeted therapeutics.
Based on the cancer type, the market has been divided into breast cancer, lung cancer, colorectal cancer, prostate cancer, stomach cancer, and others. Breast cancer biomarkers help in early identification and hormonal treatment options. Lung cancer biomarkers reveal genetic alterations, such as EGFR, which guide targeted therapy. Colorectal cancer biomarkers aid in detection and prognosis. Prostate cancer biomarkers provide risk classification, whereas stomach cancer biomarkers improve diagnosis and monitoring, hence promoting customized oncology treatments.
Based on the application, the market is classified into diagnostics, prognostics, risk assessment, drug discovery and development, and others. Diagnostics use biomarkers to identify cancer early and precisely. Prognostics predict illness progression, which aids in therapy planning. Risk assessment evaluates cancer risk based on genetics. Biomarkers help with target identification and therapy optimization in drug discovery and development, increasing personalized medicine progress and improving patient outcomes.
Based on the end user, the market is segmented into hospitals, academic and research institutions, ambulatory surgical centers, diagnostic laboratories, and others. Biomarkers are used in hospitals to diagnose and customize therapies. Academic and research institutions prioritize biomarker discovery and translational research. Ambulatory surgical centers use biomarkers to determine preoperative risk. Diagnostic laboratories use high-throughput biomarker analysis to identify and track cancer development.

Report Features	Details
Market Size in 2024	USD 1,252.6 Million
Market Forecast in 2033	USD 3,621.3 Million
Market Growth Rate 2025-2033	11.2%
Units	Million USD
Scope of the Report	Exploration of Historical and Forecast Trends, Industry Catalysts and Challenges, Segment-Wise Historical and Predictive Market Assessment: Profiling Technology Biomolecule Cancer Type Application End User Region
Profiling Technologies Covered	Omic Technologies, Imaging Technologies, Immunoassays, Cytogenetics
Biomolecules Covered	Genetic Biomarkers, Protein Biomarkers, Glyco-Biomarkers
Cancer Types Covered	Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Others
Applications Covered	Diagnostics, Prognostics, Risk Assessment, Drug Discovery and Development, Others
End Users Covered	Hospitals, Academic and Research Institutions, Ambulatory Surgical Centers, Diagnostic Laboratories, Others
Regions Covered	Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, Shikoku Region
Customization Scope	10% Free Customization
Post-Sale Analyst Support	10-12 Weeks
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Browse IMARC Related Reports on Cancer Biomarkers Market:

Need more help?

Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.

Japan Cancer Biomarkers Market Expected to Reach USD 3,621.3 Million by 2033 - IMARC Group

Purchase Options Discount
Offer

Inquire Before Buying

Benefits of Customization

Personalize this research
Triangulate with your data
Get data as per your format and definition
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization

Speak to an Analyst

Request Brochure

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

IMARC did an outstanding job in preparing our study. They were punctual and precise, delivering all the data we required in a clear and well-organized format. Their attention to detail and ability to meet deadlines was impressive, making them a reliable partner for our project.

I wanted to express my sincere appreciation for your efforts in handling this matter. Your dedication and commitment have truly been commendable. It is evident that you have put in a tremendous amount of hard work and expertise into resolving the issues at hand. I would also like to take this opportunity to inform you that we are greatly interested

Overall, the deliverable was well organized and my experience with the project team was good. In particular, I appreciated how they responded when I requested additional information and the Japanese version.

The IMARC team were extremely professional and very cooperative. The team were also extremely flexible in making changes and modifications wherever required. The entire experience right from project kick-off to after sales support was fruitful and smooth.

I’d like to express my gratitude for the work you accomplished with the industry report. The way you responded to the requirements and delivered under tight timelines shows your expertise, exceptional work ethic and commitment to your customer’s success. The entire team and company are incredibly thankful for your dedication. Once again, thank you

The market reports from IMARC have been instrumental in guiding our business strategies. We found the reports comprehensive and data-driven, which helped us make informed decisions. The detailed insights and actionable data have consistently provided us with a competitive edge in a rapidly changing alcohol market.

One of the best things about IMARC is their flexibility and predisposition to tailor the reports and adapt to our needs. They are not just great in their researching and consulting solutions, but their service is unparallelled. We’ve worked with them a couple of times and we will keep working with them in future projects.

We recently commissioned multiple market research reports from IMARC, and the insights we received were invaluable. The depth of analysis, accuracy of data, and actionable recommendations have greatly enhanced our strategic decision-making.

The market estimates provided by your team were pretty much in line with what we were theorizing internally. Really appreciate the work on this.

The sale account manager and the service was excellent. The data and market trends gathered from the report was insightful and really assisted while planning future product and growth strategies.

The report is excellent and has good amount of data and our team is extremely happy with the information provided.

Thank you very much for your cooperation and post purchase support. We were really happy with the final deliverable, and the takeaways from the report.